If this is your first visit, be sure to check out the FAQ in HCMA Announcements. You may have to register before you can post: click the register link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below. Your Participation in this message board is strictly voluntary. Information and comments on the message board do not necessarily reflect the feelings, opinions, or positions of the Hypertrophic Cardiomyopathy Association. At no time should participants to this board substitute information within for individual medical advice. The Hypertrophic Cardiomyopathy Association shall not be liable for any information provided herein. All participants in this board should conduct themselves in a professional and respectful manner. Failure to do so will result in suspension or termination. The moderators of the message board working with the HCMA will be responsible for notifying participants if they have violated the rules of conduct for the board. Moderators or HCMA staff may edit any post to ensure it conforms with the rules of the board or may delete it. This community is welcoming to all those with HCM we ask that you remember each user comes to the board with information and a point of view that may differ from that which you hold, respect is critical, please post respectfully. Thank you

Announcement

Collapse
No announcement yet.

FDA Updates Consumers on Guidant Corporation’s ICD's

Collapse

About the Author

Collapse

Lisa Salberg Find out more about Lisa Salberg
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • FDA Updates Consumers on Guidant Corporation’s ICD's

    FDA Updates Consumers on Guidant Corporation’s Implantable Defibrillators
    By U.S. Food and Drug Administration
    Jul 4, 2005, 08:28

    Email this article
    Printer friendly page

    FOR IMMEDIATE RELEASE
    P05-37
    July 1, 2005
    Media Inquiries:
    Suzanne Treviño, 301-827-6242
    Consumer Inquiries:
    888-INFO-FDA



    FDA Updates Consumers on Guidant Corporation’s Implantable Defibrillators
    As the Food and Drug Administration (FDA) continues to evaluate the safety and performance of certain implantable defibrillators manufactured by Guidant Corporation, the Agency has now classified the recalled devices. This additional information on the relative health risks of the devices will help patients and doctors take appropriate action, if necessary.

    Classifications can fall into three categories, with Class I being the most serious. These numerical classifications are based on the probability that the device failure could lead to adverse health effects.

    “Malfunctions in these devices can lead to serious consequences and it’s important for patients to call their doctor for additional information and personalized advice,” said Daniel Schultz, MD, Director of FDA’s Center for Devices and Radiological Health. “However, it’s also important to understand that in most cases these defibrillators work well and save lives.”

    Below is a full list of the 11 devices affected by this recall classification.

    PRIZM 2 DR, CONTAK RENEWAL, and CONTAK RENEWAL 2 Devices- Class I

    FDA has classified the actions taken by Guidant for some of their defibrillators as Class I recalls. In a Class I recall, there is a reasonable probability that if a particular device is malfunctioning, the malfunctioning device will cause serious adverse health consequences or death.

    The firm’s investigation determined these devices can develop an internal short circuit when attempting to deliver an electrical shock to the heart, preventing the treatment of abnormal heart rhythms. The problem is caused by deterioration of electrical insulation in the device and can only be detected after the device has already malfunctioned. The device does not give any sign of impending failure and there is no test that predicts whether the device will fail.

    Two deaths associated with these 42,000 affected devices worldwide (20,600 are still implanted) have been reported to FDA.

    The affected devices are:

    PRIZM 2 DR, Model 1861, manufactured on or before April 16, 2002
    CONTAK RENEWAL, Model H135, manufactured on or before August 26, 2004
    CONTAK RENEWAL 2, Model H155, manufactured on or before August 26, 2004
    A Class I recall designation does not necessarily require removal of the defibrillator. These recalls require Guidant to disclose the device malfunction to patients and doctors while providing additional instructions for safe use of the devices. FDA is not making a recommendation on whether patients who have one of these devices should have it removed and replaced. FDA believes that this decision must be made by the patient in consultation with his or her physician, based on the specific medical situation of the patient. Replacement of the device may pose some risk, so it is important that patients and physicians carefully discuss this matter before making a decision.

    Guidant previously informed patients and physicians about the defibrillator problems and has provided additional instructions for safe use of the devices. Guidant’s recommendations include:

    If you are not sure which model you have, or if you have other questions regarding your device, you should consult with your physician.
    Continue to keep your normal doctor appointments.
    If you feel a shock, contact your doctor as soon as possible.
    If you or others hear “beeping” from your device, go immediately to your doctor or the emergency room.
    VENTAK PRIZM AVT, VITALITY AVT, and RENEWAL AVT Devices- Class II

    FDA has classified the previous actions taken by Guidant for these devices as a Class II recall. For a Class II recall, the malfunctioning product may cause temporary or medically reversible adverse health consequences, however the probability of serious adverse health consequences is remote.

    These Guidant devices are subject to a memory error which, in rare cases, may limit available therapy. Of the 21,000 devices implanted worldwide (18,000 in the U.S.), two incidents have been confirmed, neither of which resulted in death or injury. The defect can be detected by medical evaluation of the device and Guidant is recommending the device be reprogrammed during the patient’s next doctor visit. Guidant is developing an additional non-invasive software solution for this problem, which is expected by the end of the year.

    CONTAK RENEWAL 3 and 4, RENEWAL 3 and 4 AVT, and RENEWAL RF Devices- Class II

    FDA has classified the previous actions taken by Guidant regarding these devices as a Class II recall.

    These devices are subject to a component failure that in rare cases may limit available therapy. A magnetic switch in these devices may become stuck in the closed position, which in some cases inhibits the device’s ability to treat ventricular or atrial tachyarrhythmias (abnormally fast heart rhythms) and also accelerates battery depletion. Four occurrences have been confirmed out of approximately 46,000 devices; a fifth occurrence is suspected but cannot be confirmed. In the four confirmed cases, patients and/or physicians were alerted to the condition by audible device tones signaling that the magnetic switch was closed. Based on this information, it is important that patients who hear tones from their device immediately contact their physician or go to the hospital emergency room.

    As a precautionary measure, Guidant has recommended that physicians discontinue implanting these devices until further notice. For devices already implanted, Guidant has recommended that physicians change “Enable Magnet Use” to “OFF.” This will ensure appropriate therapy to treat the patient’s abnormally fast heart rhythm.

    FDA requests that physicians support Guidant’s efforts to acquire additional information about the performance of these devices. Specifically, FDA asks doctors to test these devices at the time they are no longer in service and if possible to return the devices to the manufacturer for analysis.

    If you are a physician or a patient who has experienced a problem with any of the affected defibrillator models, please send a report to FDA's MedWatch program and to Guidant. See <http://www.fda.gov/medwatch/index.html> for filing information or call 1-800-FDA-1088 (1-800-332-1088).

    Guidant has posted information for patients and physicians on its web site at http://guidant.com/physician_communications/. If you have further questions, you may contact Guidant at 1-866-GUIDANT (1-866-484-3268).

    ####
    Knowledge is power ... Stay informed!
    YOU can make a difference - all you have to do is try!

    Dx age 12 current age 46 and counting!
    lost: 5 family members to HCM (SCD, Stroke, CHF)
    Others diagnosed living with HCM (or gene +) include - daughter, niece, nephew, cousin, sister and many many friends!
    Therapy - ICD (implanted 97, 01, 04 and 11, medication
    Currently not obstructed
    Complications - unnecessary pacemaker and stroke (unrelated to each other)

Today's Birthdays

Collapse

Working...
X